Trans-4-Isopropylcyclohexane Carboxylic Acid | CAS:7077-05-6

We serve Trans-4-Isopropylcyclohexane Carboxylic Acid CAS:7077-05-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Trans-4-Isopropylcyclohexane Carboxylic Acid

CAS No: 7077-05-6
Product Name: Trans-4-Isopropylcyclohexane Carboxylic Acid
Other Name:
Trans-4-Isopropylcyclohexane Carboxylic Acid
trans-4-(propan-2-yl)cyclohexanecarboxylic acid
 
Density: 1.0±0.1 g/cm3
Boiling Point: 263.8±8.0 °C at 760 mmHg
Melting Point: 95 °C
Molecular Formula: C10H18O2
Molecular Weight: 170.249
Flash Point: 126.9±13.1 °C
Exact Mass: 170.130676
PSA: 37.30000
LogP: 3.14
Vapour Pressure: 0.0±1.1 mmHg at 25°C
Index of Refraction: 1.470
 
Specification
Appearance: White crystalline powder
Cis isomer content (GC): ≤0.20%
Singles impurity (GC): ≤0.30%
Melting point: 92～97℃
Burningresidue: ≤0.20%
Water (K.F): ≤0.50%
Assay (GC): ≥99.30%
 
Application
Intermediates of Nateglinide CAS: 105816-04-4.
Trans-4-Isopropylcyclohexanecarboxylic acid is an intermediate used in the process for the preparation of Nateglinide, a novel D-phenylalanine-derivative hypoglycemic agent.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like Trans-4-Isopropylcyclohexane Carboxylic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trans-4-(propan-2-yl)cyclohexanecarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Trans-4-Isopropylcyclohexane Carboxylic Acid Use and application,trans-4-(propan-2-yl)cyclohexanecarboxylic acid technical grade,usp/ep/jp grade.


Related News: This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.2-nitro-1-N-phenylbenzene-1,4-diamine manufacturer This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.5-Ethyl-2-[2-(4-nitrophenoxy)ethyl]pyridine supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Methyl 3-chlorosulfonylthiophene-2-carboxylate vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.